

Part A. PERSONAL INFORMATION

CV date 2023/1/11

First and Family name	Luis-Felipe CALLADO				
Social Security, Passport, ID number	30596505L	Age	55	Gender	Male
Researcher codes	WoS Researcher ID (*)	A-7024-2008			
	SCOPUS Author ID(*)	7003769505			
	Open Researcher and Contributor ID (ORCID) **	0000-0002-5564-3447			

(*) At least one of these is mandatory

(**) Mandatory

A.1. Current position

Name of University/Institution	University of the Basque Country				
Department	Pharmacology				
Address and Country	Medical School, Sarriena Auzoa z/g, Leioa48940, Spain				
Phone number	+34946015704	E-mail	LF.callado@ehu.eus		
Current position	Full Professor		From	2021	
Key words	Cannabinoids, addiction, human brain, schizophrenia				

A.2. Education

	University	Year
PhD, Medicine	University of the Basque Country	1997
MD	University of the Basque Country	1991

A.3. JCR articles, h Index, thesis supervised...

- Number of articles included in SCI: 136
- Number of articles included in SCI in the last 5 years: 39 (26 in Q1)
- h index: 33
- Total number of times cited: 3848 (average citation per paper: 28.29)
- Most Cited Paper (652 times):
González-Maeso et al. "Identification of a Novel Serotonin/Glutamate Receptor Complex Implicated in Psychosis" *Nature* 452:93-97 (2008).
- Thesis supervised: 5 (another 3 ongoing)
- Book chapters: 32
- Peer Reviewed Conference Proceedings: 228
- Plenary lectures in Scientific Meetings: 24

Part B. CV SUMMARY (max. 3500 characters, including spaces)

Dr. Luis F. Callado has 25 years of experience in neurochemical studies and functional responses of receptors to psychoactive drugs. His work is focused on neurobiology of receptors and transduction systems in schizophrenia, drug dependence and other psychiatric disorders. Current research involves the neurochemical study of brain receptors and their role in some neuropsychiatric disorders. These studies include the use of radioligand binding techniques, biochemical assays as well as *in vivo* methods. All these techniques and methodologies are currently functioning in his laboratory.

The experience and qualifications of Dr. Callado in the field are clearly represented in the number and level of his publications: to date, he has published 136 papers in high-standard peer-reviewed journals and has presented results at several international conferences. He has on-going research collaborations with several European groups working in neuropsychopharmacology. His current research work is supported by grants funded by the governments of the Basque Country and Spain. He is also the co-IP of the G16 research group of the Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM.

Dr. Callado is a member of several professional societies, including the Spanish Pharmacological Society, the Spanish Association of Cannabinoid Research, and the Spanish

Society of Drug Abuse Research. He has been involved in the organization of several scientific meetings, and is a reviewer for several journals in the pharmacology and neuroscience areas.

Part C. RELEVANT MERITS

C.1. 10 most relevant publications in the last 5 years

1. Almodóvar-Payá C.; Guardiola-Ripoll M.; Giralte-López M.; Gallego C.; Salgado-Pineda P.; Miret S.; Salvador R.; Muñoz M.J.; Lázaro L.; Guerrero-Pedraza A.; Cuesta M.J.; Maristany T.; Sarró S.; Parellada M.; Carrión M.I.; Fañanás L.; **Callado L.F.**; Arias B.; Pomarol-Clotet E.; Fatjó-Vilas M. "NRN1 Gene as a potential marker of early-onset schizophrenia: Evidence from genetic and neuroimaging approaches". *International Journal of Molecular Sciences* 23: 7456 (2022). IF: 6.208 (Q1).
2. Segarra R.; Recio-Barbero M.; Sáenz-Herrero M.; Mentxaka O.; Cabezas-Garduño J, Eguiluz J.I.; **Callado L.F.** "Oral and Palmitate Paliperidone Long-Acting Injectable Formulations use in Schizophrenia Spectrum Disorders: a retrospective cohort study from the CRUPEP First Episode Psychosis Intervention Program". *International Journal of Neuropsychopharmacology* 24: 694-702 (2021). IF: 4.333 (Q1).
3. Soria-Gomez E.; Pagano Zottola A.C.; Mariani Y.; Desprez T.; Barresi M.; Bonilla-del-Río I.; Muguruza C.; Le Bon-Jego M.; Julio-Kalajzić F.; Flynn R.; Terral G.; Fernández-Moncada I.; Robin L.M.; Olivera da Cruz J.F.; Corinti S.; Ould Amer Y.; Goncalves J.; Varilh M.; Cannich A.; Redon B.; Zhao Z.; Lesté-Lasserre T.; Vincent P.; Tolentino-Cortes T.; Busquets-García A.; Puente N.; Bains J.S.; Hebert-Chatelain E.; Barreda-Gómez G.; Chaoulouff F.; Lohman A.W.; **Callado L.F.**; Grandes P.; Baufreton J.; Marsicano G.; Bellocchio L. "Subcellular specificity of cannabinoid effects in striatonigral circuits". *Neuron* 109: 1513-1526 (2021). IF: 14.415 (Q1).
4. Oliveira da Cruz J.F.; Ioannidou C.; Pagano Zottola A.C.; Muguruza C.; Gomez-Sotres P.; Fernandez M.; **Callado L.F.**; Marsicano G.; Busquets-Garcia A. "Sex-dependent pharmacological profiles of the synthetic cannabinoid MMB-Fubinaca". *Addiction Biology* 26:e12940 (2021). IF: 4.121 (Q1).
5. de Salas-Quiroga A.; García-Rincón D.; Gómez-Domínguez D.; Valero M.; Simón-Sánchez S.; Paraíso-Luna J.; Aguares J.; Pujadas M.; Muguruza C.; **Callado L.F.**; Lutz B.; Guzmán M.; Menendez de la Prida L.; Galve-Roperh I. "Long-term hippocampal interneuronopathy drives sex-dimorphic spatial memory impairment induced by prenatal THC exposure". *Neuropsychopharmacology* 45: 877-886 (2020). IF: 7.160 (Q1).
6. Muguruza C.; Morentin B.; Meana J.J.; Alexander SPH; **Callado L.F.** "Endocannabinoid system imbalance in the postmortem prefrontal cortex of subjects with schizophrenia". *Journal of Psychopharmacology* 33: 1132-1140 (2019). IF: 4.221 (Q1).
7. Morentin B.; **Callado L.F.** "Sudden cardiac death associated to substances of abuse and psychotropic drugs consumed by young people: A population study based on forensic autopsies". *Drug and Alcohol Dependence* 201: 23-28 (2019). IF: 3.466 (Q1).
8. Erdozain A.M.; Brocos-Mosquera I.; Gabilondo A.M.; Meana J.J.; **Callado L.F.** "Differential α_{2A} - and α_{2C} -adrenoceptor protein expression in presynaptic and postsynaptic density fractions of postmortem human prefrontal cortex". *Journal of Psychopharmacology* 33: 244-249 (2019). IF: 4.221 (Q1).
9. Ibarra-Lecue I.; Pilar-Cuellar F.; Muguruza C.; Florensa-Zanuy E.; Díaz A.; Urigüen L.; Castro E.; Pazos A.; **Callado L.F.** "The endocannabinoid system in mental disorders: Evidence from human brain studies". *Biochemical Pharmacology* 157: 97-107 (2018). IF: 4.825 (Q1).
10. Ibarra-Lecue I.; Mollinedo-Gajate I.; Meana J.J.; **Callado L.F.**; Díez-Alarcia R.; Urigüen L. "Chronic cannabis promotes pro-hallucinogenic signaling of 5-HT_{2A} receptors through Akt/mTOR pathway". *Neuropsychopharmacology* 43: 2028-2035 (2018). IF: 7.16 (Q1).

C.2. Research projects and grants as Principal Investigator:

1. "Evaluation of the endogenous cannabinoid system as a marker of vulnerability to alcoholism". Supported by the Spanish National Plan on Drug Abuse. Ministry of Health. Project 2006I045. 2006-2009. Awarded amount: 48642 €.
2. "Evaluation of the antidepressant activity of new alpha-2 adrenoceptor antagonist molecules". Supported by the Department of Industry, Commerce and Tourism of the Basque Government within the SAIOTEK Program (S-PE08UN01). 2008-2009. Awarded amount: 42276 €.
3. "Study of the therapeutic applications of new alpha-2 adrenoceptor antagonists". Supported by the Department of Industry, Commerce and Tourism of the Basque Government within the SAIOTEK Program (S-PE10UN14). 2010-2011. Awarded amount: 21238.42 €.
4. "Determination of levels of psychotropic drugs in the brain and their correlation with plasma levels". Supported by the Department of Industry, Commerce and Tourism of the Basque Government within the SAIOTEK Program (S-PE12UN033). 2012-2013. Awarded amount: 18752.69 €.
5. "Alterations of the noradrenergic system in cognitive deficits of schizophrenia: localization, mechanisms and pharmacological reversion". Supported by the Spanish Ministry of Economy and Competitiveness. Project SAF2013-48586-R. 01/01/2014-31/12/2016. Awarded amount: 157300 €.
6. General Call for Grants for the acquisition and renovation of scientific infrastructure. Supported by the UPV/EHU 2015. Awarded amount: 51110 €.
7. Neuropsychopharmacology research group of the UPV/EHU, included in the CIBER of Mental Health, CIBERSAM, (G16). Supported by the Carlos III Health Institute. Ministry of Health. Co-IP since 2017. Awarded amount: 423205 €.
8. "Susceptibility to alcohol dependence, a role for the matricellular protein hevin". Supported by the The European Foundation for Alcohol Research. 01/01/2019-31/06/2021. Awarded amount: 70000 €.
9. "Discovering the molecular mechanisms underlying the cannabis-induced increased risk of schizophrenia". Supported by the Spanish Ministry of Science and Innovation. Project PID2019-106404RB-I00. 01/06/2020-30/06/2024. Awarded amount: 130680 €.
10. Call for Grants to support the activities of the research groups of the Basque University System 2022-2025. Education Department. Basque Government. Type A (IT512-22). 01/01/22-31/12/25. Awarded amount: 502425€.

C.3. Patents

- "Guanidine based compounds and their use in the treatment of mental and neurological disorders". I. Rozas, F. Rodriguez-Royo, J.J. Meana y **L.F. Callado**. Nº Registro: WO/2009/080818. Entidades cotitulares: Trinity College Dublin y Universidad del País Vasco UPV/EHU.
- "STXBP1 as psychiatric biomarker in murine model system and their uses". M.J. Guerrero, L. Simon, M. Ferrer-Alcon, A. Martinez, J.J. Meana, **L.F. Callado** y L. Uriguen. Nº Registro: WO2010/020642. Entidades cotitulares: Brainco Biopharma y Universidad del País Vasco UPV/EHU.



- “Transgenic animal model of mood disorders”. D. Arteta, M. Ferrer, L. Simón, A. Martínez, M. Uribarri, J.J. Meana y **L.F. Callado**. Nº Registro: WO2013/1EP55253. Entidades cotitulares: Brainco Biopharma y Universidad del País Vasco UPV/EHU.
- “Synthetic 12 imidazoline receptor ligands for prevention or treatment of human brain disorders”. M.C. Escolano, M. Pallàs, C.G. Griñán, S. Abás, **L.F. Callado**, J.A. García Sevilla. Nº Registro: WO 2019/121853 A1. Entidades cotitulares: Universitat de Barcelona, Universitat de les Illes Balears y Universidad del País Vasco UPV/EHU.

C.4. Institutional responsibilities

- Director for Scientific and Social Development of the University of the Basque Country. Since 2021.
- Elected member of the Governing Council of the UPV/EHU. 2012-2021.
- Elected member Commission for Academic Planning and Doctorate. UPV/EHU. 2004-2013.
- Elected member Commission for Postgraduate studies. UPV/EHU. 2013-2017.

C5. Memberships of scientific Institutions

- Member of the Spanish CIBER of Mental Health (CIBERSAM).
- Member of the Biocruces Bizkaia Health Research Institute.

C6. Editorial Boards and Review

- Associate Editor. *Frontiers in Pharmacology*. Since 2015.
- Editorial Board member. *Journal of Schizophrenia Research*. Since 2016.
- Editorial Board member. *Trastornos Adictivos*. 2010-2014.
- Invited peer reviewer for over 40 neuroscience and pharmacology journals

C7. Scientific grants reviewer:

- Agencia Nacional de Evaluación y Prospectiva (ANEP). Spain.
- National Science Centre. Poland.
- Austrian Science Fund (FWF). Austria
- Ministero dell Istruzione, dell Università e della Ricerca. Italy.
- Spanish National Drugs Plan (PNSD). Spain
- Fundación General CSIC. Spain.
- Agencia para la Calidad del Sistema Universitario de Castilla y León (ACSUCYL). Spain
- Agencia per a la Qualitat del Sistema Universitari de Catalunya (AQU Catalunya). Spain
- Fundación Pública Andaluza Progreso y Salud. Consejería de Salud y Bienestar Social. Junta de Andalucía. Spain